ArticleMolecular medicine reports2019
TGF‑β1 upregulates the expression of lncRNA‑ATB to promote atherosclerosis.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Emerging Roles of Long Non-Coding RNAs in Cardiovascular Diseases.Journal of cellular and molecular medicine · 2025Review
- Biomarkers That Seem to Have the Greatest Impact on Promoting the Formation of Atherosclerotic Plaque in Current Scientific Research.Current issues in molecular biology · 2024Review
- Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis.Vascular pharmacology · 2024Review
- Long non-coding RNAs as biomarkers and therapeutic targets for ischemic stroke.Non-coding RNA research · 2022Review
- Cardiovascular Disease in Myeloproliferative Neoplasms:JACC. CardioOncology · 2022Review
- LncRNAs as Therapeutic Targets and Potential Biomarkers for Lipid-Related Diseases.Frontiers in pharmacology · 2021Review
- The Role of Long Non-Coding RNAs in Intracranial Aneurysms and Subarachnoid Hemorrhage.Life (Basel, Switzerland) · 2020Review
- Noncoding RNAs in Vascular Aging.Oxidative medicine and cellular longevity · 2020Review
- Silencing MMP2-AS1 inhibits the proliferation and migration of endothelial cells via YB-1.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor (TGF)‑β1 is reported to be associated with the occurrence of atherosclerosis, although the mechanism remains unclear. Therefore, the present study aimed to investigate the involvement of TGF‑β1 signaling in atherosclerosis. A total of 56 patients with atherosclerosis and 44 healthy volunteers were involved in this study. Serum expression of TGF‑β1 and long non‑coding RNA‑ATB was detected by ELISA and quantitative polymerase chain reaction (qPCR). Receiver operating characteristic curve analysis was performed to analyze the diagnostic value of serum TGF‑β1 and lncRNA‑ATB for atherosclerosis. A human umbilical vein endothelial cell (HUVEC) line overexpressing lncRNA‑ATB was constructed. The effects of TGF‑β1 treatment and lncRNA‑ATB overexpression on HUVEC cell proliferation and viability was detected with Cell Counting Kit‑8 and MTT assays, respectively. Expression of TGF‑β1 and pro‑apoptotic Caspase‑3 in lncRNA‑ATB‑overexpressing HUVECs was detected by western blotting. In addition, the expression of lncRNA‑ATB in TGF‑β1‑treated HUVECs was detected by qPCR. It was demonstrated that serum TGF‑β1 and lncRNA‑ATB expression was significantly higher in atherosclerosis patients, compared with controls, and could be used to effectively distinguish patients from healthy individuals. TGF‑β1 treatment and lncRNA‑ATB overexpression reduced HUVEC viability and proliferation. TGF‑β1 treatment increased the expression of lncRNA‑ATB in HUVECs, while lncRNA‑ATB overexpression had no significant effect on TGF‑β1 expression. LncRNA‑ATB silencing with small interfering RNA significantly reduced the effects of TGF‑β1 treatment on the proliferation and viability of HUVECs. Furthermore, LncRNA‑ATB overexpression upregulated the expression of caspase‑3 in HUVECs. Therefore, it was concluded that TGF‑β1 may have upregulated the expression of lncRNA‑ATB to promote atherosclerosis, and lncRNA‑ATB may serve as a potential therapeutic target for atherosclerosis. However, the mechanism remains to be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.